After a review of the journal article (samade, r.Et al (2022), utility of 45s5 bioactive glass as bone graft substitute for cavitary defects in pediatric bone tumors: a preliminary study, j pediatr orthop vol.42 (9), pages 532-538 (usa)), it was reported to the manufacturer on march 12, 2024 that one of the 21 patients developed a surgical site infection after treatment of an aneurysmal bone cyst.No additional information was provided about the adverse event.There is no evidence that the infection was due to the product, but this complaint is being reported out of an abundance of caution.
|